Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics' stock price has declined over the past six months, trading at $10.01 as of October 26, 2025, with a 52-week range of $7.87 to $25.00. The share price on October 10, 2025, was $9.02, representing a 64.46% decline from $25.38 on October 11, 2024. Recent news includes the report of second-quarter 2025 financial results on July 30, 2025, where regenerative solutions revenue was up 41% with the Integrity™ Implant System performing ahead of expectations and continued strong Hyalofast® growth. Despite some positive product line growth, the company reported an 8.2% decrease in revenue on an apples-to-apples basis compared to the previous year in the second quarter, and a 10% decline in international osteoarthritis pain revenue due to order timing and production yield issues, contributing to low investor sentiment.

While specific details are not provided, Anika Therapeutics' focus on osteoarthritis pain management, regenerative solutions, and sports medicine suggests potential seasonal variations. Osteoarthritis might see consistent demand, but sports-related injuries and elective surgical procedures could experience some seasonality. The robust financial performance of its Integrity product line and growth in osteoarthritis pain revenue outside the US indicate strong market demand.

Anika Therapeutics, Inc. is a life sciences company specializing in hyaluronic acid (HA)-based therapeutic products, focusing on orthobiologics and medical devices for joint health, tissue repair, and surgical applications. Their products include injectable viscosupplements like Monovisc® and Orthovisc® for knee osteoarthritis pain relief, and Euflexxa® for international markets. Anika has expanded into wound repair, surgical adhesion prevention, and dermatological applications, offering solutions like the Integrity™ Implant System and Hyalofast® for cartilage repair and regeneration. In February 2020, Anika acquired Arthrosurface, expanding its joint preservation offerings.

Anika Therapeutics has a global presence, operating through subsidiaries and distributors in North America, Europe, and Asia Pacific. Their products are commercialized in the United States, Europe, and internationally.

Anika Therapeutics scored higher than 89% of companies evaluated by MarketBeat and ranked 109th out of 943 stocks in the medical sector, suggesting a relatively strong standing within its industry. The company has a consensus rating of "Moderate Buy" from Wall Street analysts. Events affecting Anika's reputation include the reported decrease in revenue and decline in international osteoarthritis pain revenue, which have contributed to a low investor sentiment. However, the strong growth in its Integrity product line and regenerative solutions segment could positively impact its reputation for innovation and market penetration in orthopedic therapies.

Institutional investors hold a significant portion of Anika Therapeutics' stock, approximately 91.53%. Anika Therapeutics has 282 institutional owners and shareholders holding a total of 13,928,121 shares. Institutions hold 60.2% of shares, hedge funds hold 24.1%, and individual insiders hold 4.05% of the shares. Major institutional owners include Trigran Investments, Inc., BlackRock, Inc., Caligan Partners LP, Vanguard Group Inc., Dimensional Fund Advisors Lp, Opaleye Management Inc., Acadian Asset Management Llc, Boothbay Fund Management, Llc, Renaissance Technologies Llc, Alta Fundamental Advisers LLC, Geode Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., and Atria Investments Inc.